Reuters logo
10 months ago
BRIEF-Insmed announces worldwide license agreement with AstraZeneca for oral DPP1 inhibitor
October 5, 2016 / 11:21 AM / 10 months ago

BRIEF-Insmed announces worldwide license agreement with AstraZeneca for oral DPP1 inhibitor

1 Min Read

Oct 5 (Reuters) - Insmed Inc

* Insmed will pay AstraZeneca an upfront payment of $30 million

* Agreement provides AstraZeneca with option to negotiate a future agreement with Insmed for commercialization of AZD7986/ins1007

* Continue to expect patient enrollment in phase 3 study of Arikayce to conclude later this year and to report top line data in 2017

* Confirms its cash operating expense guidance for second half of 2016 of $62 million to $72 million

* In a phase 1 study of healthy volunteers AZD7986 was well tolerated

* Says AstraZeneca will be eligible to receive future payments totaling $120 mln in future clinical, regulatory, and sales-related milestones

* Confirms its cash operating expense guidance for second half of 2016 of $62 to $72 million. Source text for Eikon: Further company coverage: [INSM.O>]

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below